BioSpace News Archive

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the fourth quarter and fiscal year ended November 30, 2021 and provided a corporate update.

Peregrine Market Access, a leading life science commercialization partner, has been selected by Nonagen Bioscience to become its contract commercialization organization for Oncuria™, a breakthrough bladder cancer diagnostic test that is being developed to aid in detection, therapy choice, and disease monitoring.

ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2021.

Welltower Inc. (NYSE: WELL) today announced that it will release fourth quarter 2021 financial results after the close of trading on the New York Stock Exchange on Tuesday, February 15, 2022.

Provention Bio, Inc. today announced its intent to resubmit the teplizumab Biologics License Application.

CooperCompanies announced it will release first quarter 2022 financial results on Thursday, March 3, 2022, at 4:15 PM ET.

Participants include a syndicate of existing and new shareholders Contributes to total of $10.1 million in new equity financing for January, 2022.

AbCellera (Nasdaq: ABCL) announced today that it will report full year 2021 financial results after market close on Thursday, February 24, 2022 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock January 27, 2022.

HaemaLogiX Ltd (HaemaLogiX), and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered into an agreement to manufacture the next clinical batch (cGMP) of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab.